KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) Research & Development (2016 - 2026)

Bio-Rad Laboratories has reported Research & Development over the past 18 years, most recently at $62.9 million for Q1 2026.

  • Quarterly Research & Development fell 14.42% to $62.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $265.0 million through Mar 2026, down 12.54% year-over-year, with the annual reading at $275.6 million for FY2025, 6.86% down from the prior year.
  • Research & Development was $62.9 million for Q1 2026 at Bio-Rad Laboratories, down from $70.3 million in the prior quarter.
  • Over five years, Research & Development peaked at $91.0 million in Q3 2024 and troughed at $43.5 million in Q3 2023.
  • The 5-year median for Research & Development is $66.2 million (2022), against an average of $67.0 million.
  • Year-over-year, Research & Development plummeted 34.84% in 2023 and then soared 109.03% in 2024.
  • A 5-year view of Research & Development shows it stood at $66.2 million in 2022, then dropped by 3.53% to $63.9 million in 2023, then grew by 24.62% to $79.6 million in 2024, then decreased by 11.68% to $70.3 million in 2025, then decreased by 10.53% to $62.9 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Research & Development are $62.9 million (Q1 2026), $70.3 million (Q4 2025), and $71.3 million (Q3 2025).